Z-1312-2018 Class II Terminated
FDA device recall Z-1312-2018 was initiated by Phadia US Inc on Dec 18, 2017 and is designated Class II. Reason for recall: The stability specifications of ImmunoCAP Allergen c5, Ampicilloyl were not met. The recall status is terminated (terminated Mar 27, 2019). Affected quantity: 950 total.
Recall details
- Product Type
- Devices
- Report Date
- Apr 11, 2018
- Initiation Date
- Dec 18, 2017
- Termination Date
- Mar 27, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 950 total
Product description
ImmunoCAP Allergen c5, Ampicilloyl (article number 14-4450-01). ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of allergen specific IgE in human serum or plasma. To be used with the instrument Phadia 250, Phadia 1000, Phadia 2500 and Phadia 5000.
Reason for recall
The stability specifications of ImmunoCAP Allergen c5, Ampicilloyl were not met.
Distribution pattern
Nationwide Distribution
Code information
Lots 990DS, Exp 2017.12.31 990DT, Exp 2018.01.31 990DW, Exp 2018.03.31 990DX, Exp, 2018.05.31 990DY
Source
- Dataset
- openFDA device recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for Z-1312-2018
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026